Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Intelligent Medicine Acquisition Corp.IQMD · Entity 11509 | Director | November 04, 2021 | November 04, 2021 |
| SelectQuote, Inc.SLQT · Entity 6791 | Director | November 11, 2025 | November 14, 2025 |
| Sigilon Therapeutics, Inc.SGTX · Entity 11481 | Director | August 11, 2023 | August 11, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Intelligent Medicine Acquisition Corp.
Report date November 04, 2021 · Filed November 04, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Common StockSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2021-11-04 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: As described in the issuer's registration statement on Form S-1 (File No. 333-260205) under the heading "Description of Securities--Founder Shares", the shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination on a one-for-one basis (subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like) and subject to certain anti-dilution rights and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in the issuer's registration statement on Form S-1 (File No. 333-260205) under the heading "Description of Securities--Founder Shares", the shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination on a one-for-one basis (subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like) and subject to certain anti-dilution rights and have no expiration date.
SelectQuote, Inc.
Report date November 11, 2025 · Filed November 14, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.01 per shareSEC Table I · non-derivative | Direct | 363,214 |
Reported balance
After 2025-11-11 transaction · row 1
1 source rowRow 1 · 2025-11-11 · Exercise / conversion · Acquired 52,631 · Balance 363,214 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-11-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-11-11 · Exercise / conversion · Disposed 52,631 · Balance 0 F1: Represents restricted stock units of SelectQuote, Inc. (the "Company") granted to the recipient pursuant to the Company's 2020 Omnibus Incentive Plan. F2: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock, par value $0.01 per share. F3: The award vested in full on the transaction date shown in Column 3. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2035-11-11 | Direct | 106,250 |
Reported balance
After 2025-11-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-11-11 · Grant · Acquired 106,250 · Balance 106,250 F1: Represents restricted stock units of SelectQuote, Inc. (the "Company") granted to the recipient pursuant to the Company's 2020 Omnibus Incentive Plan. F2: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock, par value $0.01 per share. F4: The award vests in full on the date of the Company's 2026 Annual Meeting of Stockholders (the "Vesting Date"), subject to the recipient's continued service on the Company's Board of Directors as of the Vesting Date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units of SelectQuote, Inc. (the "Company") granted to the recipient pursuant to the Company's 2020 Omnibus Incentive Plan.
F2: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock, par value $0.01 per share.
F3: The award vested in full on the transaction date shown in Column 3.
F4: The award vests in full on the date of the Company's 2026 Annual Meeting of Stockholders (the "Vesting Date"), subject to the recipient's continued service on the Company's Board of Directors as of the Vesting Date.
Sigilon Therapeutics, Inc.
Report date August 11, 2023 · Filed August 11, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.28 · Expires 2033-05-18 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-08-11 · Disposition to issuer · Disposed 683 · Balance 0 F1: Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split. F2: Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one Contingent Value Right per Share subject to such stock option immediately prior to the Acceptance Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.92 · Expires 2032-05-25 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-08-11 · Disposition to issuer · Disposed 683 · Balance 0 F1: Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split. F2: Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one Contingent Value Right per Share subject to such stock option immediately prior to the Acceptance Time. |
Filing footnotes · ownership attribution and instrument terms
F1: Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split.
F2: Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one Contingent Value Right per Share subject to such stock option immediately prior to the Acceptance Time.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Arcellx, Inc.
Report date April 28, 2026 · Filed April 28, 2026
Section 16 reporting ended · disclosed 2026-04-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.66 · Expires 2031-12-07 | Direct | 0 |
Reported balance
After 2026-04-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-28 · Disposition to issuer · Disposed 27,077 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option ("Company Option"), whether or not vested, and which had a per share exercise price less than $115 per share (the "Closing Amount"), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2032-02-03 | Direct | 0 |
Reported balance
After 2026-04-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-28 · Disposition to issuer · Disposed 20,513 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option ("Company Option"), whether or not vested, and which had a per share exercise price less than $115 per share (the "Closing Amount"), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.94 · Expires 2033-06-14 | Direct | 0 |
Reported balance
After 2026-04-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-28 · Disposition to issuer · Disposed 11,459 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option ("Company Option"), whether or not vested, and which had a per share exercise price less than $115 per share (the "Closing Amount"), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $51.30 · Expires 2034-05-28 | Direct | 0 |
Reported balance
After 2026-04-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-04-28 · Disposition to issuer · Disposed 8,011 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option ("Company Option"), whether or not vested, and which had a per share exercise price less than $115 per share (the "Closing Amount"), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $63.68 · Expires 2035-05-29 | Direct | 0 |
Reported balance
After 2026-04-28 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-04-28 · Disposition to issuer · Disposed 9,174 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option ("Company Option"), whether or not vested, and which had a per share exercise price less than $115 per share (the "Closing Amount"), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option ("Company Option"), whether or not vested, and which had a per share exercise price less than $115 per share (the "Closing Amount"), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger.
TESARO, Inc.
Report date January 22, 2019 · Filed January 22, 2019
Section 16 reporting ended · disclosed 2019-01-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 1
1 source rowRow 1 · 2019-01-22 · Other · Disposed 2,757 · Balance 0 F1: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement"). |
| Director Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-01-22 · Disposition to issuer · Disposed 4,052 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F3: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. |
| Director Nonqualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.03 · Expires 2026-03-31 | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-01-22 · Disposition to issuer · Disposed 24,000 · Balance 0 F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. |
| Director Nonqualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $149.22 · Expires 2027-06-01 | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-01-22 · Disposition to issuer · Disposed 12,000 · Balance 0 F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. |
| Director Nonqualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.89 · Expires 2028-06-01 | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-01-22 · Disposition to issuer · Disposed 7,209 · Balance 0 F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. |
Filing footnotes · ownership attribution and instrument terms
F1: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement").
F2: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock.
F3: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share.
F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd]
F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 12, 2024 Filed Nov 14, 2024 21:37 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 1,500 | $106.33 | $159,495.00 |
DisclosureSEC source: 0001415889-24-026874 · form4-11142024_091117.xml · nonDerivative · entry 2 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on March 28, 2024. Read SEC document |
| November 12, 2024 Filed Nov 14, 2024 21:37 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionCommon Stock | 1,500 | $6.66 | $9,990.00 |
DisclosureSEC source: 0001415889-24-026874 · form4-11142024_091117.xml · nonDerivative · entry 1 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 11, 2024 Filed Nov 13, 2024 01:30 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionStock Option (right to buy) · Derivative | 15,238 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001415889-24-026654 · form4-11132024_011112.xml · derivative · entry 14 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,513 Underlying: Common Stock · 15,238 shares Expires 2032-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one-third (1/3rd) of the shares subject to the option will vest each year following Equity Grant Date on the same day of the month as the Equity Grant Date (or, if there is no corresponding day in a particular month, then the last day of the month) over three (3) years. "Equity Grant Date" shall mean February 3, 2022. Read SEC document |
| November 11, 2024 Filed Nov 13, 2024 01:30 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 3,005 | $106.91 | $321,259.44 |
DisclosureSEC source: 0001415889-24-026654 · form4-11132024_011112.xml · nonDerivative · entry 10 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on March 28, 2024. F7 · price: Represents the weighted average share price of an aggregate total of 3,005 shares sold in the price range of $106.34 to $107.25 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 11, 2024 Filed Nov 13, 2024 01:30 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 12,233 | $105.68 | $1,292,746.74 |
DisclosureSEC source: 0001415889-24-026654 · form4-11132024_011112.xml · nonDerivative · entry 9 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,005 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on March 28, 2024. F6 · price: Represents the weighted average share price of an aggregate total of 12,233 shares sold in the price range of $105.34 to $106.27 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 11, 2024 Filed Nov 13, 2024 01:30 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionCommon Stock | 15,238 | $15.00 | $228,570.00 |
DisclosureSEC source: 0001415889-24-026654 · form4-11132024_011112.xml · nonDerivative · entry 8 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,238 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 08, 2024 Filed Nov 13, 2024 01:30 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionStock Option (right to buy) · Derivative | 25,787 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001415889-24-026654 · form4-11132024_011112.xml · derivative · entry 13 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,751 Underlying: Common Stock · 25,787 shares Expires 2032-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one-third (1/3rd) of the shares subject to the option will vest each year following Equity Grant Date on the same day of the month as the Equity Grant Date (or, if there is no corresponding day in a particular month, then the last day of the month) over three (3) years. "Equity Grant Date" shall mean February 3, 2022. Read SEC document |
| November 08, 2024 Filed Nov 13, 2024 01:30 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionStock Option (right to buy) · Derivative | 7,976 | $0.00 Strike: $6.66 | $0.00 |
DisclosureSEC source: 0001415889-24-026654 · form4-11132024_011112.xml · derivative · entry 12 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,577 Underlying: Common Stock · 7,976 shares Expires 2031-12-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Shares issued pursuant to the Issuer's 2017 Equity Incentive Plan (the "2017 Plan"). Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2017 Plan) through each applicable date, twenty-five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean December 1, 2021. Read SEC document |
| November 08, 2024 Filed Nov 13, 2024 01:30 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 25,787 | $105.46 | $2,719,515.07 |
DisclosureSEC source: 0001415889-24-026654 · form4-11132024_011112.xml · nonDerivative · entry 7 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on March 28, 2024. F5 · price: Represents the weighted average share price of an aggregate total of 25,787 shares sold in the price range of $105.24 to $105.96 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 08, 2024 Filed Nov 13, 2024 01:30 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 2,076 | $100.57 | $208,789.34 |
DisclosureSEC source: 0001415889-24-026654 · form4-11132024_011112.xml · nonDerivative · entry 6 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,787 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on March 28, 2024. F4 · price: Represents the weighted average share price of an aggregate total of 2,076 shares sold in the price range of $100.57 to $100.58 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 08, 2024 Filed Nov 13, 2024 01:30 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 5,900 | $99.60 | $587,637.05 |
DisclosureSEC source: 0001415889-24-026654 · form4-11132024_011112.xml · nonDerivative · entry 5 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,863 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on March 28, 2024. F3 · price: Represents the weighted average share price of an aggregate total of 5,900 shares sold in the price range of $99.24 to $100.12 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 08, 2024 Filed Nov 13, 2024 01:30 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionCommon Stock | 25,787 | $15.00 | $386,805.00 |
DisclosureSEC source: 0001415889-24-026654 · form4-11132024_011112.xml · nonDerivative · entry 4 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,763 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 08, 2024 Filed Nov 13, 2024 01:30 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionCommon Stock | 7,976 | $6.66 | $53,120.16 |
DisclosureSEC source: 0001415889-24-026654 · form4-11132024_011112.xml · nonDerivative · entry 3 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,976 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 07, 2024 Filed Nov 13, 2024 01:30 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionStock Option (right to buy) · Derivative | 8,478 | $0.00 Strike: $6.66 | $0.00 |
DisclosureSEC source: 0001415889-24-026654 · form4-11132024_011112.xml · derivative · entry 11 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,553 Underlying: Common Stock · 8,478 shares Expires 2031-12-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Shares issued pursuant to the Issuer's 2017 Equity Incentive Plan (the "2017 Plan"). Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2017 Plan) through each applicable date, twenty-five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean December 1, 2021. Read SEC document |
| November 07, 2024 Filed Nov 13, 2024 01:30 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 8,478 | $99.30 | $841,861.16 |
DisclosureSEC source: 0001415889-24-026654 · form4-11132024_011112.xml · nonDerivative · entry 2 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on March 28, 2024. F2 · price: Represents the weighted average share price of an aggregate total of 8,478 shares sold in the price range of $99.24 to $99.48 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 07, 2024 Filed Nov 13, 2024 01:30 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionCommon Stock | 8,478 | $6.66 | $56,463.48 |
DisclosureSEC source: 0001415889-24-026654 · form4-11132024_011112.xml · nonDerivative · entry 1 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,478 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 22, 2024 Filed Oct 22, 2024 22:48 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionStock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $6.66 | $0.00 |
DisclosureSEC source: 0001415889-24-025533 · form4-10222024_101007.xml · derivative · entry 3 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,031 Underlying: Common Stock · 1,500 shares Expires 2031-12-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Shares issued pursuant to the Issuer's 2017 Equity Incentive Plan (the "2017 Plan"). Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2017 Plan) through each applicable date, twenty-five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean December 1, 2021. Read SEC document |
| October 22, 2024 Filed Oct 22, 2024 22:48 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 1,500 | $89.69 | $134,535.00 |
DisclosureSEC source: 0001415889-24-025533 · form4-10222024_101007.xml · nonDerivative · entry 2 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on March 28, 2024. Read SEC document |
| October 22, 2024 Filed Oct 22, 2024 22:48 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionCommon Stock | 1,500 | $6.66 | $9,990.00 |
DisclosureSEC source: 0001415889-24-025533 · form4-10222024_101007.xml · nonDerivative · entry 1 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:00 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionStock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $6.66 | $0.00 |
DisclosureSEC source: 0001415889-24-024597 · form4-10032024_081041.xml · derivative · entry 3 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,531 Underlying: Common Stock · 1,500 shares Expires 2031-12-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Shares issued pursuant to the Issuer's 2017 Equity Incentive Plan (the "2017 Plan"). Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2017 Plan) through each applicable date, twenty-five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean December 1, 2021. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:00 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 1,500 | $82.24 | $123,360.00 |
DisclosureSEC source: 0001415889-24-024597 · form4-10032024_081041.xml · nonDerivative · entry 2 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on March 28, 2024. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:00 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionCommon Stock | 1,500 | $6.66 | $9,990.00 |
DisclosureSEC source: 0001415889-24-024597 · form4-10032024_081041.xml · nonDerivative · entry 1 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 10, 2024 Filed Sep 12, 2024 22:27 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionStock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $6.66 | $0.00 |
DisclosureSEC source: 0001415889-24-023318 · form4-09122024_100945.xml · derivative · entry 3 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,031 Underlying: Common Stock · 1,500 shares Expires 2031-12-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Shares issued pursuant to the Issuer's 2017 Equity Incentive Plan (the "2017 Plan"). Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2017 Plan) through each applicable date, twenty-five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean December 1, 2021. Read SEC document |
| September 10, 2024 Filed Sep 12, 2024 22:27 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 1,500 | $74.41 | $111,615.00 |
DisclosureSEC source: 0001415889-24-023318 · form4-09122024_100945.xml · nonDerivative · entry 2 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on March 28, 2024. Read SEC document |
| September 10, 2024 Filed Sep 12, 2024 22:27 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionCommon Stock | 1,500 | $6.66 | $9,990.00 |
DisclosureSEC source: 0001415889-24-023318 · form4-09122024_100945.xml · nonDerivative · entry 1 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 20, 2024 Filed Aug 22, 2024 20:01 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionStock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $6.66 | $0.00 |
DisclosureSEC source: 0001415889-24-021996 · form4-08222024_080835.xml · derivative · entry 3 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 64,531 Underlying: Common Stock · 1,500 shares Expires 2031-12-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Shares issued pursuant to the Issuer's 2017 Equity Incentive Plan (the "2017 Plan"). Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2017 Plan) through each applicable date, twenty-five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean December 1, 2021. Read SEC document |
| August 20, 2024 Filed Aug 22, 2024 20:01 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 1,500 | $65.88 | $98,820.00 |
DisclosureSEC source: 0001415889-24-021996 · form4-08222024_080835.xml · nonDerivative · entry 2 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on March 28, 2024. Read SEC document |
| August 20, 2024 Filed Aug 22, 2024 20:01 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionCommon Stock | 1,500 | $6.66 | $9,990.00 |
DisclosureSEC source: 0001415889-24-021996 · form4-08222024_080835.xml · nonDerivative · entry 1 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 30, 2024 Filed Aug 1, 2024 21:24 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionStock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $6.66 | $0.00 |
DisclosureSEC source: 0001415889-24-020535 · form4-08012024_090809.xml · derivative · entry 4 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,031 Underlying: Common Stock · 1,500 shares Expires 2031-12-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Shares issued pursuant to the Issuer's 2017 Equity Incentive Plan (the "2017 Plan"). Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2017 Plan) through each applicable date, twenty-five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean December 1, 2021. Read SEC document |
| July 30, 2024 Filed Aug 1, 2024 21:24 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 200 | $62.95 | $12,590.00 |
DisclosureSEC source: 0001415889-24-020535 · form4-08012024_090809.xml · nonDerivative · entry 3 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on March 28, 2024. F3 · price: Represents the weighted average share price of an aggregate total of 200 shares sold in the price range of $62.84 to $63.06 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 30, 2024 Filed Aug 1, 2024 21:24 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 1,300 | $61.81 | $80,359.37 |
DisclosureSEC source: 0001415889-24-020535 · form4-08012024_090809.xml · nonDerivative · entry 2 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 200 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on March 28, 2024. F2 · price: Represents the weighted average share price of an aggregate total of 1,300 shares sold in the price range of $61.51 to $62.15 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 30, 2024 Filed Aug 1, 2024 21:24 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionCommon Stock | 1,500 | $6.66 | $9,990.00 |
DisclosureSEC source: 0001415889-24-020535 · form4-08012024_090809.xml · nonDerivative · entry 1 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 09, 2024 Filed Jul 11, 2024 20:04 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionStock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $6.66 | $0.00 |
DisclosureSEC source: 0001415889-24-019485 · form4-07112024_080702.xml · derivative · entry 4 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67,531 Underlying: Common Stock · 1,500 shares Expires 2031-12-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Shares issued pursuant to the Issuer's 2017 Equity Incentive Plan (the "2017 Plan"). Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2017 Plan) through each applicable date, twenty-five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean December 1, 2021. Read SEC document |
| July 09, 2024 Filed Jul 11, 2024 20:04 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 648 | $57.15 | $37,036.38 |
DisclosureSEC source: 0001415889-24-019485 · form4-07112024_080702.xml · nonDerivative · entry 3 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on March 28, 2024. F3 · price: Represents the weighted average share price of an aggregate total of 648 shares sold in the price range of $56.83 to $57.59 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 09, 2024 Filed Jul 11, 2024 20:04 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 852 | $56.23 | $47,910.69 |
DisclosureSEC source: 0001415889-24-019485 · form4-07112024_080702.xml · nonDerivative · entry 2 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 648 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on March 28, 2024. F2 · price: Represents the weighted average share price of an aggregate total of 852 shares sold in the price range of $55.81 to $56.63 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 09, 2024 Filed Jul 11, 2024 20:04 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionCommon Stock | 1,500 | $6.66 | $9,990.00 |
DisclosureSEC source: 0001415889-24-019485 · form4-07112024_080702.xml · nonDerivative · entry 1 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 27, 2024 Filed Jun 28, 2024 20:08 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $6.66 | $0.00 |
DisclosureSEC source: 0001415889-24-018409 · form4-06282024_080631.xml · derivative · entry 4 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,031 Underlying: Common Stock · 10,000 shares Expires 2031-12-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Shares issued pursuant to the Issuer's 2017 Equity Incentive Plan (the "2017 Plan"). Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2017 Plan) through each applicable date, twenty-five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean December 1, 2021. Read SEC document |
| June 27, 2024 Filed Jun 28, 2024 20:08 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 5,029 | $54.51 | $274,108.66 |
DisclosureSEC source: 0001415889-24-018409 · form4-06282024_080631.xml · nonDerivative · entry 3 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on March 28, 2024. F3 · price: Represents the weighted average share price of an aggregate total of 5,029 shares sold in the price range of $54.28 to $55.08 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 27, 2024 Filed Jun 28, 2024 20:08 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 4,971 | $54.02 | $268,547.84 |
DisclosureSEC source: 0001415889-24-018409 · form4-06282024_080631.xml · nonDerivative · entry 2 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,029 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on March 28, 2024. F2 · price: Represents the weighted average share price of an aggregate total of 4,971 shares sold in the price range of $53.28 to $54.27 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 27, 2024 Filed Jun 28, 2024 20:08 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionCommon Stock | 10,000 | $6.66 | $66,600.00 |
DisclosureSEC source: 0001415889-24-018409 · form4-06282024_080631.xml · nonDerivative · entry 1 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 28, 2024 Filed Jun 6, 2024 20:17 UTC | Arcellx, Inc. ACLX · Entity 15294 | GrantStock Option (right to buy) · Derivative | 8,011 | $0.00 Strike: $51.30 | $0.00 |
DisclosureSEC source: 0001415889-24-015743 · form4-06062024_080628.xml · derivative · entry 1 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,011 Underlying: Common Stock · 8,011 shares Expires 2034-05-28 F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2022 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of May 28, 2025 or the next annual meeting of stockholders. Read SEC document |
| November 14, 2023 Filed Nov 17, 2023 00:44 UTC | SelectQuote, Inc. SLQT · Entity 6791 | GrantRestricted Stock Units · Derivative | 94,890 | $0.00 | $0.00 |
DisclosureSEC source: 0001794783-23-000155 · wk-form4_1700181868.xml · derivative · entry 3 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,890 Underlying: Common Stock, par value $0.01 per share · 94,890 shares Expires not disclosed F1 · security: Represents restricted stock units of SelectQuote, Inc. (the "Company") granted to the recipient pursuant to the Company's 2020 Omnibus Incentive Plan. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock, par value $0.01 per share. F4 · derivative.exercise_date: The award vests in full on the date of the Company's 2024 annual meeting of stockholders (the "Vesting Date"), subject to the recipient's continued service on the Board of Directors as of the Vesting Date. F4 · derivative.expiration_date: The award vests in full on the date of the Company's 2024 annual meeting of stockholders (the "Vesting Date"), subject to the recipient's continued service on the Board of Directors as of the Vesting Date. Read SEC document |
| November 14, 2023 Filed Nov 17, 2023 00:44 UTC | SelectQuote, Inc. SLQT · Entity 6791 | Exercise / conversionRestricted Stock Units · Derivative | 203,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001794783-23-000155 · wk-form4_1700181868.xml · derivative · entry 2 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.01 per share · 203,125 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents restricted stock units of SelectQuote, Inc. (the "Company") granted to the recipient pursuant to the Company's 2020 Omnibus Incentive Plan. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock, par value $0.01 per share. F3 · derivative.exercise_date: The award vested in full on the transaction date reported on this line. F3 · derivative.expiration_date: The award vested in full on the transaction date reported on this line. Read SEC document |
| November 14, 2023 Filed Nov 17, 2023 00:44 UTC | SelectQuote, Inc. SLQT · Entity 6791 | Exercise / conversionCommon Stock, par value $0.01 per share | 203,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001794783-23-000155 · wk-form4_1700181868.xml · nonDerivative · entry 1 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 215,693 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 20:10 UTC | Sigilon Therapeutics, Inc. SGTX · Entity 11481 | Disposition to issuerStock Option (Right to Buy) · Derivative | 683 | $5.00 Strike: $9.92 | $3,413.91 |
DisclosureSEC source: 0001415889-23-012130 · form4-08112023_040809.xml · derivative · entry 2 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 683 shares Expires 2032-05-25 F1 · derivative.exercise_price: Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split. F2 · price: Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one Contingent Value Right per Share subject to such stock option immediately prior to the Acceptance Time. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one Contingent Value Right per Share subject to such stock option immediately prior to the Acceptance Time. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 20:10 UTC | Sigilon Therapeutics, Inc. SGTX · Entity 11481 | Disposition to issuerStock Option (Right to Buy) · Derivative | 683 | $6.64 Strike: $8.28 | $4,537.78 |
DisclosureSEC source: 0001415889-23-012130 · form4-08112023_040809.xml · derivative · entry 1 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 683 shares Expires 2033-05-18 F1 · derivative.exercise_price: Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split. F2 · price: Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one Contingent Value Right per Share subject to such stock option immediately prior to the Acceptance Time. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one Contingent Value Right per Share subject to such stock option immediately prior to the Acceptance Time. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 20:20 UTC | Arcellx, Inc. ACLX · Entity 15294 | GrantStock Option (right to buy) · Derivative | 11,459 | $0.00 Strike: $37.94 | $0.00 |
DisclosureSEC source: 0001209191-23-037838 · doc4.xml · derivative · entry 1 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,459 Underlying: Common Stock · 11,459 shares Expires 2033-06-14 F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2022 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 14, 2024 or the next annual meeting of stockholders. Read SEC document |
| May 19, 2023 Filed May 22, 2023 20:20 UTC | Sigilon Therapeutics, Inc. SGTX · Entity 11481 | GrantStock Option (Right to Buy) · Derivative | 8,888 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0001415889-23-008497 · form4-05222023_040518.xml · derivative · entry 1 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,888 Underlying: Common Stock · 8,888 shares Expires 2033-05-18 F1 · derivative.exercise_date: The option was issued pursuant to the Sigilon Therapeutics, Inc. 2020 Equity Incentive Plan. The option will vest as to 100% on May 19, 2024 Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 23:49 UTC | SelectQuote, Inc. SLQT · Entity 6791 | Exercise / conversionRestricted Stock Units · Derivative | 7,849 | $0.00 | $0.00 |
DisclosureSEC source: 0001794783-22-000102 · wf-form4_166872895029371.xml · derivative · entry 3 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.01 per share · 7,849 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents restricted stock units of SelectQuote, Inc. (the "Company") granted to the recipient pursuant to the Company's 2020 Omnibus Incentive Plan. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock, par value $0.01 per share. F4 · derivative.exercise_date: The RSUs vested in full on the transaction date shown in this row under Column 3. F4 · derivative.expiration_date: The RSUs vested in full on the transaction date shown in this row under Column 3. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 23:49 UTC | SelectQuote, Inc. SLQT · Entity 6791 | GrantRestricted Stock Units · Derivative | 203,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001794783-22-000102 · wf-form4_166872895029371.xml · derivative · entry 2 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,125 Underlying: Common Stock, par value $0.01 per share · 203,125 shares Expires not disclosed F1 · security: Represents restricted stock units of SelectQuote, Inc. (the "Company") granted to the recipient pursuant to the Company's 2020 Omnibus Incentive Plan. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock, par value $0.01 per share. F3 · derivative.exercise_date: The RSUs vest on the date of the Company's 2023 annual meeting of stockholders (the "Vesting Date"), subject to the recipient's continued service on the Company's Board of Directors as of the Vesting Date. F3 · derivative.expiration_date: The RSUs vest on the date of the Company's 2023 annual meeting of stockholders (the "Vesting Date"), subject to the recipient's continued service on the Company's Board of Directors as of the Vesting Date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.